AAPL297.04+0.03 (+0.01%) ▲|ABBV233.60+3.59 (+1.56%) ▲|ABT90.22+2.39 (+2.72%) ▲|ACN126.88+2.05 (+1.64%) ▲|ADBE197.77+2.87 (+1.47%) ▲|AMAT580.99-59.19 (-9.25%) ▼|AMD517.30-34.33 (-6.22%) ▼|AMGN347.52+2.80 (+0.81%) ▲|AMT178.51+2.08 (+1.18%) ▲|AMZN234.74+1.95 (+0.84%) ▲|AVGO380.92-11.22 (-2.86%) ▼|AXP337.37-0.71 (-0.21%) ▼|BA218.33-2.50 (-1.13%) ▼|BAC57.89+0.52 (+0.90%) ▲|BKNG168.67+0.90 (+0.53%) ▲|BLK1,016.29-35.45 (-3.37%) ▼|BMY55.85+1.15 (+2.10%) ▲|BNY147.50+1.06 (+0.72%) ▲|BRK-B492.96+4.27 (+0.87%) ▲|C145.34-0.34 (-0.23%) ▼|CAT985.22-37.06 (-3.63%) ▼|CL91.42+2.75 (+3.10%) ▲|CMCSA23.01+0.69 (+3.09%) ▲|COF197.35-3.35 (-1.67%) ▼|COP109.70+0.00 (+0.00%) ▲|COST958.86+7.51 (+0.79%) ▲|CRM153.84+3.72 (+2.48%) ▲|CSCO121.00-0.53 (-0.44%) ▼|CVS101.40+0.10 (+0.10%) ▲|CVX175.77+0.71 (+0.40%) ▲|DE591.40-7.20 (-1.20%) ▼|DHR178.80+0.61 (+0.34%) ▲|DIS103.66+1.21 (+1.18%) ▲|DUK125.25+1.73 (+1.40%) ▲|EMR143.58-6.63 (-4.41%) ▼|FDX321.20-7.59 (-2.31%) ▼|GD349.01+5.65 (+1.64%) ▲|GE355.79+0.67 (+0.19%) ▲|GEV1,039.82-87.78 (-7.78%) ▼|GILD125.63+0.76 (+0.61%) ▲|GM79.20-1.23 (-1.53%) ▼|GOOG346.27-2.51 (-0.72%) ▼|GOOGL346.86-2.70 (-0.77%) ▼|GS1,098.32-8.06 (-0.73%) ▼|HD325.59-1.03 (-0.32%) ▼|HON221.91-6.20 (-2.72%) ▼|IBM263.24+11.02 (+4.37%) ▲|INTC132.52-8.42 (-5.97%) ▼|INTU258.39+0.62 (+0.24%) ▲|ISRG402.25-0.70 (-0.17%) ▼|JNJ238.44+7.15 (+3.09%) ▲|JPM334.36+2.88 (+0.87%) ▲|KO80.19+0.66 (+0.83%) ▲|LIN514.63-2.08 (-0.40%) ▼|LLY1,107.53+5.45 (+0.49%) ▲|LMT501.23+7.63 (+1.55%) ▲|LOW214.15-0.25 (-0.12%) ▼|LRCX370.23-39.31 (-9.60%) ▼|MA488.29+4.20 (+0.87%) ▲|MCD271.95+1.85 (+0.68%) ▲|MDLZ61.06+1.55 (+2.60%) ▲|MDT80.48+1.21 (+1.53%) ▲|META563.77-0.08 (-0.01%) ▼|MMM162.01-1.22 (-0.74%) ▼|MO71.42+1.91 (+2.75%) ▲|MRK119.16+3.68 (+3.18%) ▲|MS226.52-0.58 (-0.25%) ▼|MSFT373.41+6.07 (+1.65%) ▲|MU1,049.14-162.24 (-13.39%) ▼|NEE86.46+0.38 (+0.44%) ▲|NFLX73.06+0.18 (+0.25%) ▲|NKE42.71-0.49 (-1.12%) ▼|NOW96.45+3.44 (+3.70%) ▲|NVDA200.95-7.70 (-3.69%) ▼|ORCL166.06-9.01 (-5.15%) ▼|PEP142.02+1.31 (+0.93%) ▲|PFE24.90-0.19 (-0.74%) ▼|PG150.97+3.29 (+2.23%) ▲|PLTR116.97-2.53 (-2.12%) ▼|PM177.44+4.27 (+2.47%) ▲|QCOM203.28-18.63 (-8.39%) ▼|RTX185.40+3.57 (+1.96%) ▲|SBUX101.08+0.93 (+0.93%) ▲|SCHW92.85+0.82 (+0.89%) ▲|SO94.82+1.39 (+1.49%) ▲|SPG216.79+2.22 (+1.03%) ▲|T22.92+0.82 (+3.69%) ▲|TMO467.35+3.34 (+0.72%) ▲|TMUS184.49+4.43 (+2.46%) ▲|TSLA381.24-23.81 (-5.88%) ▼|TXN302.71-29.58 (-8.90%) ▼|UBER69.70-1.73 (-2.42%) ▼|UNH408.04+1.36 (+0.33%) ▲|UNP259.48-0.43 (-0.17%) ▼|UPS105.98-1.27 (-1.18%) ▼|USB59.94+1.26 (+2.15%) ▲|V328.67+2.07 (+0.63%) ▲|VZ46.77+1.41 (+3.10%) ▲|WFC84.09+0.25 (+0.29%) ▲|WMT119.54+2.36 (+2.01%) ▲|XOM139.93+1.46 (+1.05%) ▲|AAPL297.04+0.03 (+0.01%) ▲|ABBV233.60+3.59 (+1.56%) ▲|ABT90.22+2.39 (+2.72%) ▲|ACN126.88+2.05 (+1.64%) ▲|ADBE197.77+2.87 (+1.47%) ▲|AMAT580.99-59.19 (-9.25%) ▼|AMD517.30-34.33 (-6.22%) ▼|AMGN347.52+2.80 (+0.81%) ▲|AMT178.51+2.08 (+1.18%) ▲|AMZN234.74+1.95 (+0.84%) ▲|AVGO380.92-11.22 (-2.86%) ▼|AXP337.37-0.71 (-0.21%) ▼|BA218.33-2.50 (-1.13%) ▼|BAC57.89+0.52 (+0.90%) ▲|BKNG168.67+0.90 (+0.53%) ▲|BLK1,016.29-35.45 (-3.37%) ▼|BMY55.85+1.15 (+2.10%) ▲|BNY147.50+1.06 (+0.72%) ▲|BRK-B492.96+4.27 (+0.87%) ▲|C145.34-0.34 (-0.23%) ▼|CAT985.22-37.06 (-3.63%) ▼|CL91.42+2.75 (+3.10%) ▲|CMCSA23.01+0.69 (+3.09%) ▲|COF197.35-3.35 (-1.67%) ▼|COP109.70+0.00 (+0.00%) ▲|COST958.86+7.51 (+0.79%) ▲|CRM153.84+3.72 (+2.48%) ▲|CSCO121.00-0.53 (-0.44%) ▼|CVS101.40+0.10 (+0.10%) ▲|CVX175.77+0.71 (+0.40%) ▲|DE591.40-7.20 (-1.20%) ▼|DHR178.80+0.61 (+0.34%) ▲|DIS103.66+1.21 (+1.18%) ▲|DUK125.25+1.73 (+1.40%) ▲|EMR143.58-6.63 (-4.41%) ▼|FDX321.20-7.59 (-2.31%) ▼|GD349.01+5.65 (+1.64%) ▲|GE355.79+0.67 (+0.19%) ▲|GEV1,039.82-87.78 (-7.78%) ▼|GILD125.63+0.76 (+0.61%) ▲|GM79.20-1.23 (-1.53%) ▼|GOOG346.27-2.51 (-0.72%) ▼|GOOGL346.86-2.70 (-0.77%) ▼|GS1,098.32-8.06 (-0.73%) ▼|HD325.59-1.03 (-0.32%) ▼|HON221.91-6.20 (-2.72%) ▼|IBM263.24+11.02 (+4.37%) ▲|INTC132.52-8.42 (-5.97%) ▼|INTU258.39+0.62 (+0.24%) ▲|ISRG402.25-0.70 (-0.17%) ▼|JNJ238.44+7.15 (+3.09%) ▲|JPM334.36+2.88 (+0.87%) ▲|KO80.19+0.66 (+0.83%) ▲|LIN514.63-2.08 (-0.40%) ▼|LLY1,107.53+5.45 (+0.49%) ▲|LMT501.23+7.63 (+1.55%) ▲|LOW214.15-0.25 (-0.12%) ▼|LRCX370.23-39.31 (-9.60%) ▼|MA488.29+4.20 (+0.87%) ▲|MCD271.95+1.85 (+0.68%) ▲|MDLZ61.06+1.55 (+2.60%) ▲|MDT80.48+1.21 (+1.53%) ▲|META563.77-0.08 (-0.01%) ▼|MMM162.01-1.22 (-0.74%) ▼|MO71.42+1.91 (+2.75%) ▲|MRK119.16+3.68 (+3.18%) ▲|MS226.52-0.58 (-0.25%) ▼|MSFT373.41+6.07 (+1.65%) ▲|MU1,049.14-162.24 (-13.39%) ▼|NEE86.46+0.38 (+0.44%) ▲|NFLX73.06+0.18 (+0.25%) ▲|NKE42.71-0.49 (-1.12%) ▼|NOW96.45+3.44 (+3.70%) ▲|NVDA200.95-7.70 (-3.69%) ▼|ORCL166.06-9.01 (-5.15%) ▼|PEP142.02+1.31 (+0.93%) ▲|PFE24.90-0.19 (-0.74%) ▼|PG150.97+3.29 (+2.23%) ▲|PLTR116.97-2.53 (-2.12%) ▼|PM177.44+4.27 (+2.47%) ▲|QCOM203.28-18.63 (-8.39%) ▼|RTX185.40+3.57 (+1.96%) ▲|SBUX101.08+0.93 (+0.93%) ▲|SCHW92.85+0.82 (+0.89%) ▲|SO94.82+1.39 (+1.49%) ▲|SPG216.79+2.22 (+1.03%) ▲|T22.92+0.82 (+3.69%) ▲|TMO467.35+3.34 (+0.72%) ▲|TMUS184.49+4.43 (+2.46%) ▲|TSLA381.24-23.81 (-5.88%) ▼|TXN302.71-29.58 (-8.90%) ▼|UBER69.70-1.73 (-2.42%) ▼|UNH408.04+1.36 (+0.33%) ▲|UNP259.48-0.43 (-0.17%) ▼|UPS105.98-1.27 (-1.18%) ▼|USB59.94+1.26 (+2.15%) ▲|V328.67+2.07 (+0.63%) ▲|VZ46.77+1.41 (+3.10%) ▲|WFC84.09+0.25 (+0.29%) ▲|WMT119.54+2.36 (+2.01%) ▲|XOM139.93+1.46 (+1.05%) ▲|
20.6 C
New York
Tuesday, June 23, 2026

Tag: hospital

newssourceFORcompanyinformationcontent1marketreleases

Llusern Scientific Announces ISO 13485 Certification for its Point-of-Care Diagnostics System for Urinary Tract Infections

CARDIFF, United Kingdom, June 17, 2025 (GLOBE NEWSWIRE) -- Llusern Scientific, a point-of-care diagnostics company, announces it has been awarded ISO 13485 certification for its Lodestar DX testing system, a rapid molecular diagnostic platform for urinary tract infections (UTIs). With industry-leading accuracy and speed, Lodestar DX empowers clinicians to diagnose and rule-out infections with precision in a single visit, thereby improving patient outcomes.

Johnson & Johnson Launches New TECNIS Odyssey Next-Generation Intraocular Lens in Europe, the Middle East, and Canada Offering Cataract Patients Precise Vision at Every...

The new full visual range*1 IOL enables 93% of patients to become free from glasses at all distances.**2 *** With best-in-class image contrast and low-light performance,#~3,4,5...

HIMSS and Informa Markets Partner to Accelerate Digital Health Transformation with Co-Located Conferences in Malaysia for International Healthcare Week

KUALA LUMPUR, Malaysia, June 17, 2025 /PRNewswire/ -- The Healthcare Information and Management Systems Society (HIMSS) has partnered with Informa Markets to co-locate the 2025...

Obras Sociais Irmã Dulce Honored with 2025 Lions International Humanitarian Award

OAK BROOK, Ill., June 16, 2025 /PRNewswire/ -- Obras Sociais Irmã Dulce (OSID), a nonprofit organization that offers free healthcare for people in need...

En termes d’efficacité, une comparaison indirecte des traitements suggère un avantage significatif d’IMBRUVICA® (ibrutinib) associé au vénétoclax par rapport à l’acalabrutinib associé au vénétoclax...

Les résultats d’études croisées de l’association ibrutinib et vénétoclax en première intention montrent un bénéfice clinique significatif pour une durée fixe, ainsi qu’une probabilité accrue de maladie résiduelle minimale indétectable et de survie sans progression par rapport à l’association acalabrutinib et vénétoclax1

NorthStar Anesthesia Expands Partnership with AdventHealth to Deliver Premier Anesthesia Care at AdventHealth Ottawa

IRVING, Texas and OTTAWA, Kan., June 16, 2025 /PRNewswire/ -- NorthStar Anesthesia, a leading anesthesia care organization serving hospitals and ambulatory surgery centers nationwide,...

“Luminous Path, Shared Stride – Brazil and China”

SHANGHAI, June 16, 2025 /PRNewswire/ -- Brazil's HIHUB.TECH delegation embarked on a landmark visit to Shanghai, exploring cutting-edge advancements in healthcare and aesthetic medicine. ...

RayStation used for pioneering clinical milestone at Helsinki University Hospital – first treatment with accelerator-based BNCT in Europe

STOCKHOLM, June 16, 2025 /PRNewswire/ -- RaySearch Laboratories AB (publ) is pleased to announce that RayStation®*, its advanced treatment planning system, was used in...

SDP Japan Raises $31 Million in Series D Round

Pioneering the Future of Surgical Care in Response to Rising DemandTOKYO, June 15, 2025 /PRNewswire/ -- SDP Japan, Inc. (Shibuya-ku, Tokyo; CEO: Kazuhiko Nagayo),...

Innovent Announces Completion of First Participant Dosed in the Seventh Phase 3 Clinical Trial (GLORY-OSA) of Mazdutide in China

SAN FRANCISCO and SUZHOU, China, June 15, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL

ROCKVILLE, Md. and SUZHOU, China, June 15, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that results from 13 studies of its core assets, including the novel drug olverembatinib (HQP1351) and the investigational EED inhibitor APG-5918, have been reported at the 2025 European Hematology Association (EHA) Annual Congress.

1000 Miglia 2025 蓄势待发

世界最美赛事重返意大利公路 
世界最美赛事重返意大利公路

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsHospital

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers